San Diego, CA -- (SBWIRE) -- 03/08/2017 -- An investor, who purchased NASDAQ:ANTH shares, filed a lawsuit in California over alleged Securities Laws violations by Anthera Pharmaceuticals Inc.

Investors who purchased shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) have certain options and for certain investors are short and strict deadlines running. Deadline: April 17, 2017. NASDAQ:ANTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The plaintiff alleges on behalf of purchasers of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) common shares between February 10, 2015 and December 27, 2016, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between February 10, 2015 and December 27, 2016, Anthera Pharmaceuticals Inc made materially false and/or misleading statements concerning the potential efficacy and success of its Solution Study and CHABLIS-SC1 clinical trials, as the Company failed to disclose that patients were not improving in the CHABLIS-SC1 clinical trial, and that there were dosing problems inherent in the Solution Study design that created challenges to obtaining responses.

On December 27, 2016, Anthera Pharmaceuticals Inc announced that its SOLUTION Phase 3 Study for liprotamase also failed to meet its primary endpoint. The Company announced it would conduct a new study of liprotamase. Shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) declined to as low as $0.64 per share on December 30, 2016.

Those who purchased shares of Anthera Pharmaceuticals Inc have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com